Leerink Partnrs Issues Optimistic Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Stock analysts at Leerink Partnrs boosted their Q1 2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics in a note issued to investors on Monday, February 24th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will earn ($1.25) per share for the quarter, up from their previous forecast of ($1.33). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share. Leerink Partnrs also issued estimates for CRISPR Therapeutics’ Q2 2025 earnings at ($1.28) EPS, Q3 2025 earnings at ($1.29) EPS, Q4 2025 earnings at ($1.34) EPS and FY2026 earnings at ($5.09) EPS.

CRSP has been the topic of several other research reports. Morgan Stanley boosted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an “underweight” rating in a report on Friday, February 14th. Royal Bank of Canada reduced their price target on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday, February 12th. Stifel Nicolaus lowered their price objective on shares of CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating for the company in a research note on Thursday, February 13th. Barclays upped their target price on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 12th. Finally, The Goldman Sachs Group decreased their price target on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating for the company in a research report on Thursday, February 13th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $43.62 on Wednesday. The firm has a 50 day moving average price of $42.36 and a 200 day moving average price of $45.99. CRISPR Therapeutics has a fifty-two week low of $36.52 and a fifty-two week high of $90.62. The company has a market capitalization of $3.74 billion, a PE ratio of -9.98 and a beta of 1.67.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings data on Tuesday, February 11th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%.

Institutional Investors Weigh In On CRISPR Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of CRSP. Wilmington Savings Fund Society FSB acquired a new position in CRISPR Therapeutics in the third quarter valued at $40,000. Ameriflex Group Inc. acquired a new stake in shares of CRISPR Therapeutics in the 4th quarter valued at about $36,000. Darwin Wealth Management LLC purchased a new position in CRISPR Therapeutics during the 3rd quarter worth approximately $43,000. Highline Wealth Partners LLC acquired a new position in CRISPR Therapeutics during the fourth quarter worth approximately $39,000. Finally, Western Pacific Wealth Management LP lifted its stake in CRISPR Therapeutics by 100.0% in the fourth quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock valued at $39,000 after buying an additional 500 shares during the last quarter. 69.20% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $55.10, for a total transaction of $826,500.00. Following the completion of the sale, the chief executive officer now owns 181,540 shares in the company, valued at approximately $10,002,854. The trade was a 7.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.10% of the stock is currently owned by corporate insiders.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.